Prostate cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Prostate cancer
- Therapeutic area
- Oncology
- prostate cancer
- prostate neoplasm
- prostatic neoplasm
- tumor of the prostate
- tumour of the prostate
- cancer of prostate gland
- malignant neoplasm of prostate
- malignant neoplasm of prostate gland
- malignant neoplasm of the prostate
- malignant prostate gland neoplasm
- malignant prostate neoplasm
- malignant prostate tumor
- malignant prostate tumour
- malignant tumor of prostate
- malignant tumor of the prostate
- malignant tumour of prostate
- malignant tumour of the prostate
- prostate gland cancer
- hereditary prostate cancer
- prostate cancer, familial
- Severity
- Terminal
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0008315
- Parent condition
- MONDO:0005836
Related records
Broader conditions (16)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Male reproductive organ cancer
- Male reproductive system disorder
- Male reproductive system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Prostate disorder
- Prostate neoplasm
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (44)
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Adenosquamous prostate carcinoma
- Castration-resistant prostate carcinoma
- Familial prostate carcinoma
- Grade III prostatic intraepithelial neoplasia
- Hormone-resistant prostate carcinoma
- Lymphoepithelioma-like acinar prostate adenocarcinoma
- Malignant prostate phyllodes tumor
- Metastatic prostate carcinoma
- Primary prostate urothelial carcinoma
- Prostate adenocarcinoma
- Prostate adenoid cystic carcinoma
- Prostate angiosarcoma
- Prostate cancer, hereditary
- Prostate cancer, hereditary, 1
- Prostate cancer, hereditary, 10
- Prostate cancer, hereditary, 11
- Prostate cancer, hereditary, 12
Trials (6,435)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
- (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
- (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
- [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
- [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
- [18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
- [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
- [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
- [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
- [18F]PSMA-11 PET/CT Phase 3 Clinical Study
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
- [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
- [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
- [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
- [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
Approved drugs (24)
- Abiraterone acetate
- Apalutamide
- Autologous peripheral-blood mononuclear cells including A minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor
- Cabazitaxel
- Choline C-11
- Darolutamide
- Degarelix acetate
- Docetaxel
- Docetaxel anhydrous
- Enzalutamide
- Fluciclovine F18
- Histrelin acetate
- Leuprolide acetate
- Leuprolide mesylate
- Lutetium LU-177 vipivotide tetraxetan
- Mitoxantrone hydrochloride
- Nilutamide
- Olaparib
- Padeliporfin potassium
- Piflufolastat F18
Drugs in development (560)
- 2-deoxy-D-glucose Phase 1
- Abarelix Phase 3
- ABBV-744 Phase 1
- ABC-294640 Phase 2
- Abemaciclib Phase 2
- Abiraterone Phase 3
- Abiraterone decanoate Phase 1
- Abituzumab Phase 2
- Abivertinib Phase 2
- ABT-751 Phase 1
- Acapatamab Phase 1
- Acetaminophen Phase 1
- Acetazolamide Phase 1
- Acyclovir sodium Phase 2
- Acyline Phase 2
- Adavosertib Phase 2
- Adebrelimab Phase 2
- Adecatumumab Phase 2
- Adenosine diphosphate Phase 2
- Afuresertib Phase 1
Other linked drugs (30)
- Acetic acid C-11
- Alisertib
- Capromab
- Cetrelimab
- Choline
- Cyproterone
- Dexmedetomidine
- Eltanexor
- Fentanyl
- Fluorocholine F-18
- Gebasaxturev
- Ifosfamide
- Indole-3-carbinol
- Iofolastat I 123
- Lidocaine
- Lutetium LU-177 psma-R2
- Mannitol
- Methotrexate
- Methylselenocysteine
- OBI-3424